Inclusion criteria: Participants with a locally advanced or metastatic solid tumor that has progressed on or is intolerant to standard therapy, or for which no standard therapy exists. Prior multikinase inhibitors (MKIs) with anti-RET activity are allowed.
Sponsor/Collaborator: Loxo Oncology, Inc.|Eli Lilly and Company
Contact and Locations:
There may be multiple sites in this clinical trial
Phone Number: 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
Email: ClinicalTrials.gov@lilly.com
Locations: https://classic.clinicaltrials.gov/ct2/show/NCT03157128
Mechanism of action: Selpercatinib, also known as LOXO-292, is a highly selective and potent, oral inhibitor for the treatment of patients with cancers that harbor abnormalities in the RET kinase.
Phases: Phase 1, Phase 2
NCT Number: NCT03157128
Status: Recruiting
